A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Aug 20, 2024

China’s National Medical Products Administration (NMPA) Approves PADCEV^TM (enfortumab vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer

- Approval based on the global EV-301 and China EV-203 trials, where enfortumab vedotin signficantly improved overall survival (OS) and objective response rate (ORR) respectively in patients following prior treatment with platinum-based chemotherapy and PD-1/L1 inhibitors1,2

TOKYO, August 20, 2024 – Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has...

Read more
Aug 1, 2024

Notice Regarding Change in fair value of contingent consideration

TOKYO, August 1, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it booked ¥5.5 billion in the first quarter of fiscal year 2024 for change in the fair value of contingent...

Read more
Jul 29, 2024

Astellas Receives Positive CHMP Opinion for PADCEV^TM (enfortumab vedotin) in combination with KEYTRUDA^® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care for those with unresectable or metastatic urothelial cancer

TOKYO, July 26, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...

Read more
Jul 26, 2024

Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer

- If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union

TOKYO, July 26, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on July 26, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European...

Read more
Jul 22, 2024

Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy

- Collaborative Research on Innovative Cartilage Organoid Cell Therapy for Intervertebral Disc Degenerative Disease using Astellas’ Universal Donor Cell Technology -

TOKYO and Osaka, July 22, 2024 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Graduate School of Medicine / Faculty of Medicine, Osaka University (President: Shojiro Nishio “Osaka University”) today announced...

Read more
Jul 2, 2024

China’s National Medical Products Administration Approves XTANDI^® (enzalutamide) in Metastatic Hormone-Sensitive Prostate Cancer

- Approval marks XTANDI’s third indication for advanced prostate cancer in China -

TOKYO, July 2, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved...

Read more
May 30, 2024

U.S. FDA ACKNOWLEDGES ASTELLAS’ RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE

If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction cancers as the first and only CLDN18.2-targeted therapy in the U.S.

TOKYO, May 30, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the company’s resubmission of the Biologics License Application (BLA) for zolbetuximab...

Read more
May 21, 2024

Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies

- Focuses on digitizing cell manufacturing processes through robotics technology

TOKYO, May 21, 2024 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it signed a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA) to begin...

Read more
May 15, 2024

Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme

TOKYO, May 15, 2024– Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “the Company”) today announced that at the meeting of the Board of Directors held today, a resolution...

Read more
May 15, 2024

Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives

TOKYO, May 15, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “the Company”) announced that at the meeting of the Board of Directors...
held today, a resolution was passed to continue the Performance-linked Stock
Compensation Scheme for the Corporate Executives

Read more

Show per page

Discover more

Media contacts

Return to media homepage

Subscribe to news alerts

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa

Choose Language

News